We studied platelet function in 41 patients with subarachnoid hemorrhage who were randomized to receive either nimodipine or placebo in a double-blind fashion. Nimodipine was given to 21 patients, intravenously for 7-10 days and then orally until 21 days after the subarachnoid hemorrhage. The other 20 patients received placebo in a similar manner. Nimodipine did not significantly influence platelet aggregability. For the first 1-5 days after the subarachnoid hemorrhage, nimodipine treatment did not have any notable effect on adenosine diphosphateinduced platelet thromboxane B 2 release, but a significant (p<0.05) inhibitory effect was observed thereafter. During intravenous administration, nimodipine prevented the increase in thromboxane release otherwise observed after subarachnoid hemorrhage. Concomitant with the decrease in thromboxane release, nimodipine increased the platelet count both before and after surgery so that the capacity for thromboxane formation per liter of blood decreased less than expected on the basis of thromboxane release per 10 7 platelets. Our study suggests that nimodipine might diminish the chance of cerebral ischemia by inhibiting platelet thromboxane release. Recently, calcium channel blocking agents have received much attention in the prevention of cerebral vasospasm and ischemia. It has been assumed that the contraction of cerebral arterial smooth muscle cells, which is calcium dependent, can be inhibited after SAH by preventing the influx of extracellular calcium.
D elayed ischemic deterioration is an impor-
tant cause of disability and death in patients with subarachnoid hemorrhage (SAH) who have survived the primary insult.
1 - 4 The pathogenesis of cerebral ischemia and cerebral artery vasospasm is obscure and may be precipitated by many factors. 2 -4 Recently, calcium channel blocking agents have received much attention in the prevention of cerebral vasospasm and ischemia. It has been assumed that the contraction of cerebral arterial smooth muscle cells, which is calcium dependent, can be inhibited after SAH by preventing the influx of extracellular calcium. 25 Platelet-derived thromboxane may be associated with cerebral ischemia after SAH because thromboxane is an effective vasoconstrictor and platelet aggregating agent. 6 We studied, in a double-blind manner, adenosine diphosphate (ADP)-induced platelet aggregability and the associated release of thromboxane in selected SAH patients who were randomized to receive nimodipine or placebo.
Subjects and Methods
We included 41 patients admitted <96 hours after the onset of SAH to the Department of Neurosurgery at the Helsinki University Central Hospital who had been enrolled in a prospective double-blind placebocontrolled study of nimodipine after aneurysmal SAH. 7 Twenty-one patients received nimodipine, and the other 20 received a placebo administered in a similar manner.
Patients who had used nonsteroidal anti-inflammatory drugs during the 2 weeks before admission were excluded from the study. No patient had salicylates in the urine on admission, and following admission no nonsteroidal anti-inflammatory drugs were given. Patients who were operated on were routinely given 4 mg i.m. betamethasone every 6 hours, starting the day before surgery and continuing until 6 days after surgery, in diminishing doses. The patient's clinical grade on admission and before surgery was classified according to Hunt and Hess. 8 The SAH was verified by computed tomography (CT) in 40 patients and by lumbar puncture and surgery in one patient. All CT examinations were performed <48 hours after the onset of SAH either before referral in the primary hospital or on admission. The amount of subarachnoid blood on the CT scan at admission was categorized according to Fisher et al 9 as 1) no evidence of subarachnoid blood, 2) diffuse deposits or a thin layer in the fissures and vertical cisterns, or 3) localized clots or a thick layer in the fissures and vertical cisterns.
Thirty-eight patients were operated on. The median time from SAH (day 0) to surgery was 5.0 (range 0.7-23) days because of variation in the timing of surgery for supratentorial aneurysms in a second study. 10 The initial dose of nimodipine or placebo was 0.25 /ig/kg/min by continuous infusion administered via an infusion pump. After 2 hours, the dose was increased to 0.5 jug/kg/min, which was maintained until 7-10 days after the onset of SAH and for at least 3 days after surgery if the patient was operated on >8 days from SAH. After intravenous administration, nimodipine or placebo was administered orally for up to 21 days after the SAH. The oral dose was 60-mg tablets every 4 hours.
From one to six blood samples were drawn from each patient for platelet function studies. The mean time of the first sample (early phase, at the beginning of treatment) was 3.0 (range 1-5) days after SAH, that of the second sample (intermediate phase, at the end of intravenous administration) was 8.6 (range 7-10) days, and that of the third sample (late phase, during oral administration) was 14.5 (range [11] [12] [13] [14] [15] [16] [17] [18] days. Three patients were sampled only after the early phase. Not all patients with an early-phase sample had samples during the intermediate or late phases due to death, coincidence of the sampling time and a weekend, or discharge to other hospitals. Blood samples were taken 4 hours after the oral administration of nimodipine or placebo. Postoperative samples were collected >2 days after surgery to decrease the effect of medication associated with anesthesia. The first sample during each phase was included in the analysis of platelet aggregability, but these were not always the same samples used for the analysis of thromboxane release since the latter was determined only from samples showing irreversible (secondary-phase) platelet aggregation. Accordingly, in some patients different samples served for the analyses of platelet aggregability and thromboxane release.
To study the release of thromboxane from platelets (measured as the concentration of the stable metabolite thromboxane B 2 [TXB 2 ]), we applied the method of ADP-induced platelet aggregation 11 described in detail elsewhere. 12 We used 8 /JM ADP on the basis of our earlier observation. 12 ADP is believed to be a physiological inducer of platelet aggregation.
13 TXB 2 formation in 11 blood was calculated as the product of TXB 2 release and the blood platelet count. This variable reflects the capacity of blood to release thromboxane. Platelet studies were performed by one laboratory technician who was blinded to the case histories of the patients.
A neurologic examination was performed daily after admission to record deterioration in the level of consciousness and development of neurologic deficits. CT scans were obtained on admission, after clinical deterioration, and on discharge. By delayed ischemic deterioration with fixed neurologic deficit we mean the gradual development of totally or partially irreversible focal neurologic signs and/or deterioration in the level of consciousness not due to intracerebral hematoma, rebleeding, hydrocephalus, clipping of an arterial branch along with the aneurysm, infection, or serum electrolyte disorders. These causes of deterioration were excluded by CT, routine postoperative angiography, laboratory investigations, or autopsy.
Outcome was assessed at 6 months according to the three-point Glasgow Outcome Scale 14 as independent state (good recovery or moderate disability), dependent state (severe disability or persistent vegetative state), or death.
The data were analyzed using BMDP. 15 Fisher's exact two-tailed test and the sign test were used to compare platelet aggregability between and within treatment groups. The results of TXB 2 release and formation capacity were analyzed after logarithmic transformation, which was necessary due to their skewed distributions. TXB 2 values and timing of surgery are given as median ± standard error of the median (SE). Other interval scale values are expressed as mean ± standard error of the mean (SEM) or mean±standard deviation (SD). We compared the treatment groups during each phase using Student's or Welch's t tests. In patients without missing data, the effect of time after SAH, treatment group, and possible confounding factors (delayed ischemic deterioration, amount of subarachnoid blood seen on the admission CT scan, age, sex, and clinical grade on admission) were compared using repeated-measures analyses of variance and covariance.
Results
The treatment groups did not differ by baseline characteristics (Tables 1 and 2 ). The timing of surgery was uniformly distributed over days 1 to 10 after SAH. The interval between the onset of SAH and the initiation of intravenous nimodipine or placebo averaged 1.9 (range 0.7-4.4) days. The time of blood sampling did not differ according to treatment group. Outcome tended to be somewhat better in the nimodipine group (Table 2) .
Nimodipine had no significant effect on platelet aggregability (data not shown); 74% of aggregations were irreversible during the early phase. Aggregability increased according to time after SAH, so that all aggregations were irreversible from the end of the first week on. Irreversible (secondary-phase) platelet aggregation was verified from the aggregation curves. The aggregation curves of the patients (measured as the maximal percentage change in light transmittance within 5 minutes) did not differ between groups (data not shown), and there were no differences between groups when preoperative and postoperative samples were analyzed separately (data not shown).
Mean ± SEM platelet counts of the nimodipine group were 208.3±12. 4 (p<0.05) in the nimodipine group than in the placebo group. A similar trend was seen when preoperative and postoperative samples were analyzed separately (data not shown). There was a very highly significant increase (p<0.001) in the platelet count according to time after SAH in both groups.
Thromboxane B 2 release increased significantly (/><0.01) after SAH in the placebo group but not in the nimodipine group. During the early phase TXB 2 release was low in both groups, and we observed no significant difference between them (Table 3) . However, samples drawn during the intermediate phase differed significantly ( Table 3 ), indicating that treatment with intravenous nimodipine inhibits the increase in TXB 2 release that otherwise develops after SAH. The difference was significant, regardless of whether the samples were collected before or after surgery. During the late phase (i.e., during oral administration of the drug) the difference persisted, although it was no longer significant; the range of values was large (Table 3) .
Because thrombocytosis developed in association with nimodipine treatment, the capacity of blood to form thromboxane was not influenced by nimodipine as much as expected according to measurements of TXB 2 release (Table 4) (8, 190 .0+2,617.0 fmol/10 7 platelets) during the late phase. There was no significant difference in the occurrence of delayed ischemic deterioration with fixed neurologic deficit between groups, probably because of the small number of patients. In both groups two patients deteriorated due to postoperative ischemia, and two patients in the nimodipine group and three in the placebo group deteriorated due to preoperative ischemia.
Among patients without cerebral ischemia nimodipine significantly (p<0.05) inhibited platelet TXB 2 release from the early phase on, while no significant effect could be detected in the patients who developed ischemia because they were too few. However, patients who deteriorated due to ischemia and received nimodipine also had lower TXB 2 release than patients with ischemia who received placebo The TXB 2 formation capacity was significantly higher (/><0.05) in patients with preoperative ischemia than in other patients during the early phase and significantly higher (p<0.05) in patients with postoperative ischemia than in patients without cerebral ischemia during the late phase. Platelet count, platelet aggregability, and aggregation percentage did not differ according to the presence of cerebral ischemia.
Discussion
Recent double-blind placebo-controlled studies have demonstrated a beneficial effect of nimodipine in the prevention of cerebral ischemic symptoms and cerebral infarctions after SAH.
-

16
- 19 Nimodipine, a 1,4-dihydropyridine, seems to decrease the incidence and severity of ischemic neurologic deficits without preventing the narrowing of major cerebral arteries visualized by angiography.
-
22 Accordingly, there must also be mechanisms other than vasospasm to cause deficits.
Calcium channel blocking agents may exert their effects by dilating leptomeningeal collateral arteries (not visualized in angiography), 25 by antiplatelet effects, Nifedipine has been shown to decrease platelet function after a single 20-mg dose in patients with coronary disease. 23 Nicardipine and acetylsalicylic acid given simultaneously in low doses have an additional antiaggregatory effect on platelets. 24 In an animal experiment, nimodipine decreased TXB 2 concentration in the arterial wall after exposure to a periarterial hematoma. 26 In another exper- iment, nimodipine had no effect on plasma TXB 2 concentrations in a systemic artery and an internal jugular vein after global cerebral ischemia lasting 11 minutes achieved by occlusion of the superior vena cava and aorta. 27 Rodriguez y Baena et al 28 showed that nimodipine had no effect on the concentrations of thromboxane and other prostaglandins (D 2 ,1 2 ) in the cerebrospinal fluid after SAH. These authors also showed that prostaglandin levels were higher in perianeurysmatic cisterns than in the lumbar cerebrospinal fluid. 28 In our study, the post-SAH increase of TXB 2 release was inhibited by intravenous nimodipine treatment, although platelet aggregability was not decreased. Nimodipine decreased TXB 2 release significantly in those patients who did not deteriorate due to ischemia and less markedly in those who developed cerebral ischemia.
The effect of nimodipine on TXB 2 release was less remarkable when the drug was given orally. The maximal serum concentration of nimodipine occurs approximately 1 hour after an oral dose. 29 Since we took blood samples approximately 4 hours after oral administration of the drug, we do not know whether low serum concentrations explain the modest effect of treatment with oral nimodipine on platelet TXB 2 release.
We do not know why the platelet count was increased more in the nimodipine group than in the placebo group. This could be associated with a negative feedback mechanism compensating for the decreased TXB 2 release due to nimodipine. Increased platelet TXB 2 release after SAH could be one mechanism involved in the prevention of rebleeding. If this is the case, an increase in the platelet count could compensate for the decreased TXB 2 release induced by nimodipine and maintain effective hemostasis after SAH. In spite of the increased platelet count in the nimodipine group, capacity of the blood to form TXB 2 tended to remain lower in the nimodipine group than in the placebo group after the early phase.
The majority of patients will not suffer, although they do increase their thromboxane release. Those who have an exceptionally high thromboxane release may develop ischemic symptoms, which may be ameliorated by nimodipine. The mechanism by which nimodipine acts on platelet TXB2 release is unknown, but it could be by inhibiting calcium influx into platelets, which can inhibit the phospholipase A 2 activity necessary for thromboxane production from arachidonic acid. If thromboxane release is decreased by nimodipine, vasoconstriction of the resistant vessels and platelet aggregability may be attenuated, leading to better local and collateral circulations.
In conclusion, we observed decreased platelet TXB 2 release caused by nimodipine treatment in patients with SAH. Accordingly, nimodipine may increase cerebral blood flow and decrease delayed cerebral ischemia via antiplatelet effects.
